<p>Ambrisentan is indicated for the treatment of&nbsp;pulmonary arterial hypertension&nbsp;(PAH) (WHO Group 1):</p>

<ul>
	<li>To improve exercise ability and delay clinical worsening.</li>
	<li>In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.</li>
</ul>

<p>Studies establishing effectiveness included predominantly patients with WHO Functional Class II&ndash;III symptoms and etiologies of&nbsp;idiopathic&nbsp;or&nbsp;heritable&nbsp;PAH (60%) or PAH associated with&nbsp;connective tissue&nbsp;diseases (34%).</p>